Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Slow Titration Clear all
Terminated Phase 2 Interventional Results available

A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes

NCT07030868
View directory record Official record
Conditions
Obesity, Overweight, Type 2 Diabetes
Interventions
LY3549492, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
38
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Greenbrae, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder

NCT00156715
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychotic Disorder, Substance Abuse, Alcohol Abuse
Interventions
Quetiapine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
4
States / cities
Augusta, Georgia • Lebanon, New Hampshire • Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Study of Urate Elevation in Parkinson's Disease, Phase 3

NCT02642393
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Inosine, Placebo
Drug
Lead sponsor
Michael Alan Schwarzschild
Other
Eligibility
30 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 29, 2026, 2:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia

NCT05462340
View directory record Official record
Conditions
Schizophrenia
Interventions
[18F]ASEM, [18F]AZAN
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 29, 2026, 2:55 PM EDT
Terminated Phase 4 Interventional Results available

Fluoxetine vs Aripiprazole Comparative Trial (FACT)

NCT02357849
View directory record Official record
Conditions
Attenuated Psychosis Syndrome
Interventions
Aripiprazole, Fluoxetine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
12 Years to 25 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 29, 2026, 2:55 PM EDT
Terminated Not applicable Interventional

Determination of Upper Airway Collapsibility During Routine CPAP Titration

NCT02566278
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Upper airway collapsibility (Pcrit)
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson's Disease

NCT02224664
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PF-06649751
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
Fountain Valley, California • Long Beach, California • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder

NCT00382291
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Regular Titration, Placebo, Slow Titration
Drug
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 17 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Buprenorphine Used With Treatment Resistant Depression in Older Adults

NCT02181231
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
venlafaxine XR, buprenorphine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 29, 2026, 2:55 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

NCT06643728
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Results available

A Study of L-DOPA for Depression and Slowing in Older Adults

NCT02744391
View directory record Official record
Conditions
Major Depressive Disorder, Dysthymia, Depression Not Otherwise Specified, Decreased Processing Speed, Decreased Gait Speed
Interventions
Levodopa
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 29, 2026, 2:55 PM EDT
Recruiting Not applicable Interventional

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

NCT06906640
View directory record Official record
Conditions
Chronic Kidney Disease(CKD), Type 2 DM, Type 2 Diabetes Mellitus (T2DM)
Interventions
(IRIS-CKD Management Program): Education, (IRIS-CKD Management Program): GDMT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • St. Petersburg, Florida • Ann Arbor, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity

NCT06854952
View directory record Official record
Conditions
Overweight or Obesity
Interventions
TERN-601, Matching Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 29, 2026, 2:55 PM EDT
Terminated Phase 3 Interventional Results available

Tecfidera Slow-Titration Study

NCT02428231
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Long Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 29, 2026, 2:55 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Multinight CPAP for Sleep Apnea Patients

NCT02635100
View directory record Official record
Conditions
Sleep Apnea, Sleep Disordered Breathing
Interventions
CPAP machine with MNT algorithm
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Depressed Mood Improvement Through Nicotine Dosing 2

NCT04433767
View directory record Official record
Conditions
Depressive Disorder
Interventions
Transdermal Nicotine patch
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia

NCT02841241
View directory record Official record
Conditions
Septic Shock
Interventions
Esmolol
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Not applicable Interventional

Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease

NCT03173781
View directory record Official record
Conditions
Parkinson's Disease
Interventions
droxidopa, Placebo
Drug
Lead sponsor
Colorado Springs Neurological Associates
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Results available

The Efficacy of Doxazosin for Cocaine Users

NCT00880997
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Doxazosin, Placebo
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Metformin to Augment Low Milk Supply (MALMS) Study

NCT02179788
View directory record Official record
Conditions
Low Milk Supply, Pre-diabetes, Insulin Resistance, Suppressed Lactation
Interventions
Standard care, Metformin, Placebo
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
20 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Early Phase 1 Interventional

Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response

NCT02871349
View directory record Official record
Conditions
Autism Spectrum Disorder
Interventions
Propranolol, Placebo, Magnetic Resonance Imaging (MRI)
Drug · Device
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
7 Years to 24 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Results available

Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder

NCT00282828
View directory record Official record
Conditions
Social Phobia
Interventions
Sertraline, Venlafaxine, Placebo, Clonazepam
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
La Jolla, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 14, 2013 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effect of KarXT in Participants With Schizophrenia

NCT06572449
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
18 Years to 65 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Los Alamitos, California • Riverside, California • Hollywood, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 29, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

NCT07011797
View directory record Official record
Conditions
Obesity
Interventions
CX11, Placebo
Drug · Other
Lead sponsor
Corxel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
17
States / cities
Phoenix, Arizona • Inglewood, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 29, 2026, 2:55 PM EDT